News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,086 Results
Type
Article (39741)
Company Profile (248)
Press Release (660097)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204189)
Career Advice (2008)
Deals (35421)
Drug Delivery (95)
Drug Development (81056)
Employer Resources (172)
FDA (16189)
Job Trends (14865)
News (345232)
Policy (32547)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49444)
ALS (95)
Alzheimer's disease (1385)
Antibody-drug conjugate (ADC) (132)
Approvals (16187)
Artificial intelligence (265)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11637)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (176)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (292)
Cancer (2322)
Cardiovascular disease (179)
Career advice (1677)
Career pathing (30)
CAR-T (156)
Cell therapy (439)
Cervical cancer (20)
Clinical research (66096)
Collaboration (857)
Company closure (2)
Compensation (569)
Complete response letters (19)
COVID-19 (2592)
CRISPR (41)
C-suite (251)
Cystic fibrosis (102)
Data (2337)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6382)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (121)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (97)
Earnings (87077)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112674)
Executive appointments (746)
FDA (17571)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (775)
Gene editing (109)
Generative AI (20)
Gene therapy (315)
GLP-1 (719)
Government (4432)
Grass and pollen (4)
Guidances (162)
Healthcare (18820)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (125)
Indications (29)
Infectious disease (2737)
Inflammatory bowel disease (143)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (98)
Interviews (312)
IPO (16530)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (325)
Lymphoma (157)
Machine learning (9)
Management (58)
Manufacturing (329)
MASH (77)
Medical device (13385)
Medtech (13390)
Mergers & acquisitions (19468)
Metabolic disorders (708)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (94)
Neuropsychiatric disorders (27)
Neuroscience (1945)
NextGen: Class of 2025 (6513)
Non-profit (4480)
Now hiring (40)
Obesity (371)
Opinion (205)
Ovarian cancer (81)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (154)
Partnered (22)
Patents (245)
Patient recruitment (116)
Peanut (46)
People (57353)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20595)
Phase II (29114)
Phase III (21677)
Pipeline (1385)
Policy (147)
Postmarket research (2563)
Preclinical (8763)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (385)
Real estate (5907)
Recruiting (65)
Regulatory (22328)
Reports (48)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (132)
Series B (91)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (51)
The Weekly (30)
Vaccines (699)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (123)
Last 7 days (993)
Last 30 days (3247)
Last 365 days (32440)
2025 (11981)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54085)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37886)
Australia (6194)
California (6435)
Canada (2072)
China (539)
Colorado (274)
Connecticut (281)
Delaware (159)
Europe (81416)
Florida (958)
Georgia (216)
Idaho (57)
Illinois (547)
India (25)
Indiana (323)
Iowa (11)
Japan (173)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (923)
Massachusetts (4783)
Michigan (226)
Minnesota (406)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1798)
New Mexico (28)
New York (1813)
North Carolina (992)
North Dakota (8)
Northern California (2842)
Ohio (210)
Oklahoma (14)
Oregon (34)
Pennsylvania (1431)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (26)
South Dakota (1)
Southern California (2415)
Tennessee (106)
Texas (956)
United States (24098)
Utah (188)
Virginia (152)
Washington D.C. (64)
Washington State (566)
West Virginia (3)
Wisconsin (57)
700,086 Results for "equillium inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Equillium Announces Feedback from the U.S. Food and Drug Administration
April 24, 2025
·
5 min read
Press Releases
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504
May 1, 2025
·
6 min read
Press Releases
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists
May 7, 2025
·
5 min read
Inflammatory bowel disease
Equillium’s Itolizumab Goes Toe-to-Toe With Humira in Ulcerative Colitis
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than Humira’s 20% at the same time point.
February 7, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
March 28, 2025
·
9 min read
Biotech Beach
Equillium to be included in the Russell Microcap® Index - June 12, 2024
Equillium, Inc. announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24.
June 12, 2024
·
5 min read
Deals
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 5, 2024
Equillium, Inc. today announced that on May 31, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 7,200 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan.
June 5, 2024
·
4 min read
Biotech Beach
Equillium to Present at the Jefferies Global Healthcare Conference
Equillium, Inc. today announced that it will present at the Jefferies Global Healthcare Conference taking place at the Marriott Marquis in New York, NY, June 4 – 6, 2024.
May 29, 2024
·
4 min read
Press Releases
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
March 28, 2025
·
10 min read
Deals
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Equillium, Inc. today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan.
April 3, 2024
·
4 min read
1 of 70,009
Next
